Publication | Closed Access
1300P A phase Ib/II trial of AK104 (PD-1/CTLA-4 bispecific antibody) in combination with anlotinib in advanced NSCLC
23
Citations
0
References
2021
Year
Advanced NsclcImmunologyAntibody ScreeningImmune Checkpoint InhibitorAntibody EngineeringImmunotherapeuticsPharmacotherapyPhase Ib/ii TrialImmunotherapyMedicineRadiation Oncology
No additional data available for this publication yet. Check back later!